cytomegaloviru
cmv
alway
one
frequent
identifi
pathogen
solid
organ
transplant
despit
multipl
prevent
strategi
develop
time
lung
transplant
recipi
among
solid
organ
transplant
recipi
appear
particularli
suscept
cmv
diseas
recurr
antivir
resist
earli
era
lung
transplant
prior
widespread
use
ganciclovirbas
prophylaxi
symptomat
cmv
diseas
includ
cmv
pneumon
common
occur
patient
highestrisk
group
identifi
donorseroposit
recipientseroneg
group
correspond
introduct
cmv
donor
organ
recipi
without
anteced
cmv
immun
thu
limit
abil
least
initi
limit
viral
replic
studi
zeevi
other
develop
cmvspecif
immun
shown
delay
lung
recipi
although
develop
immun
eventu
earli
studi
cmv
diseas
donor
cmvseroposit
serolog
associ
wors
outcom
includ
increas
risk
bo
shorter
time
bo
andor
mortal
studi
use
cmv
prophylaxi
associ
decreas
mortal
delay
onset
bo
mechan
cmv
effect
allograft
area
activ
research
studi
anim
model
rat
tracheal
allograft
support
hypothesi
caus
role
cmv
oblit
bronchiol
accentu
cmv
prevent
ganciclovir
prophylaxi
hyperimmun
serum
model
cmv
effect
accompani
increas
tumor
necrosi
factoralpha
express
decreas
express
wieb
et
al
found
rat
cmv
bacteri
infect
increas
chronic
airway
reject
rat
model
process
associ
increas
express
intercellular
adhes
molecul
icam
endothelium
well
increas
number
infiltr
leukocyt
posit
macrophag
recent
cmv
associ
increas
activ
proinflammatori
chemokin
cxcl
increas
cxcl
ip
cmvposit
bal
sampl
associ
decreas
studi
weseslindtn
et
al
weigt
et
al
found
pulmonari
cmv
associ
increas
level
chemokin
ccl
ccl
ccl
predict
bo
develop
ccl
predict
mortal
addit
role
recipi
genet
polymorph
determin
cmv
risk
gener
increas
interest
includ
polymorph
affect
interferongamma
level
recent
work
suggest
cmv
level
epitheli
line
fluid
relev
plasma
studi
assess
put
associ
cmv
bo
allograft
dysfunct
summar
tabl
recent
impact
treat
cmv
pneumon
prophylaxi
era
reassess
studi
show
dispar
result
decreas
impact
continu
advers
impact
cmv
pneumon
allograft
function
report
tamm
et
al
studi
lung
recipi
includ
cmv
pneumonia
treat
ganciclovir
without
cmv
pneumonia
signific
differ
bo
patient
surviv
year
also
associ
cmv
donorrecipi
serostatu
bo
surviv
snyder
et
al
howev
report
associ
treat
cmv
pneumon
bo
patient
transplant
biopsi
perform
includ
cmv
immunostain
cmv
pneumon
develop
treat
cmv
pneumon
within
first
month
increas
risk
bo
hazard
ratio
death
hazard
ratio
remain
signific
multivari
analysi
similarli
valentin
et
al
assess
impact
respiratori
infect
due
varieti
pathogen
found
cmv
pneumon
first
day
increas
bo
risk
hazard
ratio
anoth
studi
valentin
et
al
report
indefinit
ganciclovir
prophylaxi
associ
longterm
freedom
cmv
pneumon
group
patient
stop
prophylaxi
develop
cmv
pneumon
develop
bo
within
year
thu
controversi
still
exist
evid
suggest
least
role
cmv
current
era
sever
import
differ
emerg
compar
earlier
era
cmv
pneumon
notabl
declin
compris
exampl
set
respiratori
infect
lung
recipi
studi
valentin
et
al
longerterm
viral
suppress
becom
option
avail
oral
valganciclovir
random
multicent
studi
cmv
event
sever
significantli
decreas
group
receiv
month
compar
month
valganciclovir
prophylaxi
benefit
maintain
year
singlecent
subgroup
whether
enhanc
freedom
cmv
event
improv
lifespan
allograft
still
question
mention
studi
valentin
et
al
increas
cmv
pneumon
bo
group
stop
prophylaxi
led
group
call
indefinit
longterm
prophylaxi
addit
method
cmv
detect
becom
increasingli
sophist
especi
develop
quantit
measur
blood
bal
viral
load
allow
detect
earli
andor
subclin
infect
particular
recent
attent
lung
compart
blood
plasma
also
increas
recognit
solid
organ
transplant
recipi
import
subclin
cmv
infect
allograft
function
eg
cardiac
allograft
vasculopathi
heart
recipi
whether
earli
detect
particularli
late
cmv
cessat
prophylaxi
improv
allograft
function
lung
recipi
also
remain
shown
given
result
bauer
et
al
regard
cmv
detect
epitheli
line
fluid
question
whether
monitor
viremia
adequ
earli
detect
dispar
result
group
current
era
may
also
reflect
subtl
differ
exampl
role
mix
infect
one
cmv
genotyp
area
activ
research
although
cmv
receiv
attent
multipl
organ
describ
possibl
trigger
bo
includ
viral
bacteri
fungal
organ
tabl
herpesviru
famili
includ
herp
simplex
viru
varicellazost
viru
cmv
epsteinbarr
viru
ebv
human
herpesviru
human
kaposi
sarcoma
herpesviru
along
cmv
term
betaherpesvirus
virus
caus
roseola
infant
reactiv
posttranspl
often
earlier
timefram
cmv
reactiv
particular
describ
caus
clinic
syndrom
similar
cmv
includ
pneumon
hepat
meningoenceph
pancytopenia
pneumon
identifi
one
caus
appar
cultureneg
interstiti
pneumon
bone
marrow
transplant
recipi
herpesvirus
list
ebv
report
associ
bo
similar
syndrom
neurohr
et
al
perform
panel
viral
pcr
test
bal
fluid
lung
recipi
found
detect
patient
independ
risk
factor
bo
death
hand
ross
et
al
found
possibl
associ
detect
bronchiol
obliteran
organ
pneumonia
lung
transplant
possibl
role
ebv
studi
engelmann
et
al
monitor
lung
transplant
recipi
cmv
antigenemia
assay
ebv
dna
adenoviru
dna
blood
half
patient
ebv
dna
detect
least
one
occas
repeat
ebv
dna
detect
associ
bo
risk
diagnosi
bo
prior
studi
entri
retransplant
use
sirolimu
everolimu
associ
detect
ebv
latter
find
somewhat
surpris
sirolimu
group
immunosuppress
agent
thought
protect
effect
respect
viral
infect
compar
immunosuppress
agent
contrast
studi
recent
studi
manuel
et
al
viral
pcr
detect
bal
show
associ
cmv
one
hand
bo
acut
reject
although
half
patient
cmv
detect
onefifth
detect
differ
baselin
patient
popul
immunosuppress
prophylaxi
detect
method
might
account
differ
find
remain
larg
unexplain
manuel
et
al
hypothes
prolong
antivir
prophylaxi
prevent
viral
reactiv
within
allograft
might
mitig
damag
effect
although
report
associ
bo
detect
herpesvirus
intrigu
dispar
result
differ
center
must
introduc
note
caution
assess
impact
virus
overal
lung
transplant
recipi
highli
suscept
infect
communityacquir
respiratori
virus
carv
particularli
time
intensifi
immunosuppress
infect
may
asymptomat
may
involv
upper
lower
respiratori
tract
occasion
infecti
syndrom
sever
enough
warrant
icu
admiss
mechan
ventil
addit
dramat
symptomat
episod
howev
less
symptomat
truli
chronic
infect
also
document
even
compar
underr
ubiquit
rhinoviru
major
question
regard
carv
addit
direct
infecti
syndrom
produc
indirect
longerlast
effect
allograft
mechan
investig
recent
attent
focus
increas
chemokin
receptor
cxcr
chemokin
ligand
weigt
et
al
compar
bal
fluid
carv
noncarvinfect
lung
recipi
found
elev
level
cxcl
cxcl
correl
greater
decreas
measur
month
initi
infect
episod
multipl
studi
demonstr
impact
commun
respiratori
viral
infect
allograft
function
acut
infecti
process
also
month
resolut
although
result
vari
kumar
et
al
studi
patient
compar
patient
clinic
diagnos
viral
respiratori
infect
asymptomat
nasopharyng
throat
swab
reveal
viral
pathogen
twothird
group
clinic
respiratori
infect
includ
rhinoviru
coronaviru
respiratori
syncyti
viru
rsv
influenza
parainfluenza
human
metapneumoviru
incid
acut
reject
declin
month
significantli
higher
viral
respiratori
infect
group
patient
declin
sustain
year
recent
prospect
studi
group
util
multiplex
panel
molecular
detect
assay
virus
bal
sampl
lung
recipi
eightyon
bal
sampl
posit
virus
rhinoviru
detect
smaller
number
recipi
parainfluenza
coronaviru
influenza
metapneumoviru
rsv
acut
reject
declin
month
occur
virusposit
vs
virusneg
patient
p
true
regardless
whether
viral
infect
symptomat
anoth
studi
gottlieb
et
al
follow
lung
recipi
nasopharyng
oropharyng
viral
swab
commun
respiratori
virus
found
patient
manifest
carv
infect
bo
occur
year
carvposit
patient
vs
carvneg
patient
p
rsv
parainfluenza
viru
appear
effect
rhinoviru
coronaviru
symptomat
carv
remain
risk
factor
bo
multivari
analys
appear
influenc
progress
preexist
bo
khalifah
et
al
follow
adult
lung
recipi
found
carv
infect
associ
bo
death
death
bo
studi
effect
particularli
strong
lowertract
carv
infect
studi
vilchez
et
al
parainfluenza
viru
especi
strongli
associ
subsequ
bo
studi
shown
impact
carv
studi
pediatr
lung
recipi
liu
et
al
found
half
develop
carv
infect
infect
associ
chronic
allograft
dysfunct
death
particular
cohort
anoth
report
pediatr
lung
recipi
multicent
studi
liu
et
al
carv
infect
associ
decreas
surviv
acut
reject
studi
adult
lung
recipi
milston
et
al
found
onethird
develop
carv
infect
associ
subsequ
graft
dysfunct
soccal
et
al
perform
bal
nasopharyng
swab
found
upper
respiratori
bal
sampl
virusposit
acut
reject
associ
viral
infect
recoveri
lung
function
significantli
slower
infect
reject
present
final
vu
et
al
perform
analysi
pool
studi
confirm
associ
respiratori
viral
infect
symptom
bo
thu
studi
provid
evid
favor
associ
carv
infect
bo
confirm
analysi
pool
studi
multicent
studi
would
interest
involv
uniform
monitor
assay
protocol
potenti
effect
antivir
therapi
preserv
allograft
function
discuss
section
treatment
wherea
cmv
infect
decreas
frequenc
bacteri
infect
remain
common
posttranspl
complic
studi
valentin
et
al
lung
pathogen
current
era
bacteri
half
pseudomona
aeruginosa
bacteri
infect
gener
identifi
risk
factor
bo
pseudomona
particular
interest
note
sinc
earli
day
lung
transplant
infect
colon
pseudomona
spp
includ
multidrugresist
strain
extrem
common
lung
recipi
wherea
mani
cf
bronchiectasi
patient
colon
pseudomona
pretranspl
pseudomona
may
also
acquir
de
novo
posttranspl
recipi
associ
intens
inflammatori
respons
one
studi
botha
et
al
de
novo
acquisit
pseudomona
associ
increas
risk
bo
within
year
vs
p
pseudomona
colon
preced
bo
median
day
gottlieb
et
al
report
pseudomona
colon
posttranspl
cf
patient
risk
bo
wherea
erad
previou
pseudomona
colon
associ
less
frequent
bo
p
addit
varieti
enter
e
coli
klebsiella
enterobact
proteu
etc
nonenter
gramneg
organ
stenotrophomona
alcaligen
acinetobact
etc
may
isol
posttranspl
bal
cultur
particularli
patient
airway
complic
andor
protract
posttranspl
recoveri
ventil
cours
burkholderia
cepacia
complex
associ
high
mortal
posttranspl
particularli
b
cenocepacia
genomovar
iii
although
much
mortal
due
direct
infecti
syndrom
rather
longterm
effect
colon
gramposit
organ
includ
methicillinresist
staphylococcu
aureu
mrsa
increasingli
identifi
signific
caus
posttranspl
morbid
gupta
et
al
report
gramposit
infect
occur
lung
recipi
mostli
aureu
mrsa
mrsa
acquir
donor
relat
pretranspl
colon
recipi
acquir
de
novo
posttranspl
sourc
donor
studi
gupta
et
al
gramposit
lung
infect
associ
risk
develop
bo
also
surgic
airway
complic
valentin
et
al
identifi
gramposit
gramneg
infect
associ
increas
risk
bo
mycobacteri
infect
although
less
common
convent
bacteri
infect
also
associ
morbid
set
decreas
surviv
lung
transplant
case
mycobacterium
tuberculosi
morbid
larg
relat
direct
infecti
syndrom
wherea
colon
nontubercul
mycobacteria
associ
spectrum
clinic
manifest
includ
asymptomat
colon
whether
nontubercul
mycobacteri
infect
predispos
bo
yet
uncertain
studi
huang
et
al
nontubercul
mycobacteri
infect
associ
increas
mortal
independ
bo
possibl
mechan
allograft
effect
bacteri
colon
might
includ
increas
neutrophil
inflammatori
respons
lead
releas
cytokin
chemokin
upregul
predisposit
infect
includ
viral
fungal
infect
might
addit
increas
risk
bo
borthwick
et
al
report
pseudomona
serv
cofactor
epithelialtomesenchym
transit
implic
pathogenesi
bo
intrigu
possibl
relationship
pseudomona
colon
gastroesophag
reflux
explor
vo
et
al
subtl
difficulttocultur
organ
chlamydophila
pneumonia
chlamydia
recent
attract
interest
particularli
organ
may
respons
azithromycin
chlamydophila
pneumonia
best
detect
pcr
bal
fluid
rather
cultur
organ
studi
varieti
nontranspl
set
affin
endothelium
glanvil
et
al
report
c
pneumonia
detect
bal
sampl
lung
recipi
associ
higher
risk
earli
mortal
acut
reject
bo
anoth
studi
kotsimbo
et
al
chlamydia
statu
associ
bo
incid
wherea
low
antic
pneumonia
titer
donor
high
antic
pneumonia
titer
recipi
found
predict
freedom
bo
suggest
stronger
anteced
recipi
immun
c
pneumonia
might
help
amelior
effect
donorderiv
c
pneumonia
allograft
husain
et
al
investig
novel
chlamydialik
organ
simkania
negevensi
lung
recipi
studi
found
detect
negevensi
frequent
recipi
associ
concomit
acut
reject
effect
negevensi
chronic
allograft
dysfunct
yet
known
howev
acut
reject
risk
factor
bo
associ
acut
reject
confirm
might
also
mean
associ
longerterm
bo
risk
interestingli
clostridium
difficil
coliti
although
infect
affect
lung
directli
associ
increas
risk
bo
studi
gunderson
et
al
particularli
c
difficil
occur
earli
posttranspl
period
whether
earli
c
difficil
marker
complic
predispos
bo
whether
inflammatori
milieu
induc
c
difficil
infect
respons
need
studi
fungal
infect
particularli
aspergillosi
long
identifi
sourc
morbid
mortal
lung
transplant
recipi
risk
factor
describ
section
prevent
tradit
fungal
process
defin
invas
fungal
infect
colon
effect
fungal
infect
allograft
less
frequent
studi
viral
bacteri
infect
valentin
et
al
identifi
fungal
pneumonia
signific
risk
factor
subsequ
bo
recent
intrigu
evid
weigt
et
al
demonstr
aspergillu
colon
even
absenc
invas
infect
risk
factor
bo
bosrel
mortal
independ
acut
reject
aspergillu
colon
preced
bo
median
day
studi
howev
neither
fungal
colon
pulmonari
fungal
infect
identifi
risk
factor
chronic
allograft
dysfunct
studi
pediatr
lung
recipi
liu
et
al
although
pulmonari
fungal
infect
associ
greater
mortal
larg
multicent
pediatr
cohort
would
interest
determin
whether
differenti
effect
differ
antifung
prophylaxi
strategi
chang
landscap
antifung
prophylaxi
particularli
shift
toward
voriconazol
away
itraconazol
interest
although
antifung
prophylaxi
tradit
undertaken
goal
prevent
invas
fungal
infect
perhap
result
weigt
et
al
describ
prompt
reassess
current
antifung
prophylaxi
strategi
eye
decreas
colon
well
particular
could
ask
addit
substitut
inhal
amphotericin
liposom
amphotericin
prepar
might
lead
decreas
airway
fungal
colon
compar
systemiconli
antifung
strategi
longterm
benefit
allograft
explor
follow
section
assum
infect
predispos
bo
although
case
group
organ
evid
includ
dissent
evid
review
cmv
pose
signific
risk
bo
develop
import
question
whether
key
risk
factor
symptomat
cmv
diseas
subclin
viremia
subclin
replic
lung
compart
discuss
summar
tabl
studi
suggest
benefici
effect
cmv
prophylaxi
decreas
bo
risk
varieti
prevent
strategi
effect
prevent
symptomat
cmv
diseas
prevent
subclin
viremia
like
requir
longer
prophylaxi
preemptiv
therapi
sinc
asymptomat
viremia
might
otherwis
occur
without
detect
mention
valentin
et
al
call
indefinit
prophylaxi
relat
find
group
stop
prophylaxi
high
rate
cmv
pneumon
progress
bo
within
year
random
control
trial
palmer
et
al
known
cmv
outcom
significantli
decreas
cours
valganciclovir
prophylaxi
compar
cours
whether
benefit
translat
improv
longterm
result
allograft
need
investig
cmv
prophylaxi
might
also
work
decreas
replic
herpesvirus
ebv
sinc
impact
virus
allograft
controversi
see
yet
conclud
mechan
contributori
method
cmv
prevent
includ
avoid
cmv
exposur
patient
includ
use
cmvfree
blood
blood
transfus
need
develop
cmv
vaccin
futur
highestrisk
group
transform
dr
pretranspl
vaccin
risk
cmv
might
amelior
significantli
group
recent
studi
glycoprotein
b
cmv
vaccin
promis
pretranspl
patient
regard
commun
respiratori
virus
import
method
prevent
immun
influenza
rigor
infect
control
influenza
immun
shown
safe
transplant
recipi
larger
studi
corrobor
clinic
signific
increas
reject
allograft
dysfunct
solid
organ
transplant
recipi
efficaci
influenza
vaccin
may
suboptim
particularli
recipi
recent
transplant
intensifi
immunosuppress
per
current
guidelin
partial
protect
prefer
immun
also
extrem
import
famili
member
health
care
worker
immun
decreas
risk
transmiss
influenza
patient
transplant
recipi
acquir
influenza
despit
measur
earli
detect
antivir
treatment
reduc
morbid
includ
need
icu
admiss
import
get
messag
primari
care
provid
urgent
care
emerg
room
clinician
may
rather
transplant
team
first
assess
transplant
recipi
viral
ill
year
type
circul
influenza
strain
pattern
antivir
resist
differ
clinician
follow
yearli
updat
nation
health
organ
year
recommend
antivir
therapi
respiratori
viru
stringent
hospit
infect
control
essenti
outbreak
respiratori
infect
includ
rsv
parainfluenza
devast
transplant
ward
earli
viral
detect
nasopharyng
swab
even
minim
symptomat
patient
import
limit
inhospit
transmiss
adher
recommend
precaut
hand
hygien
essenti
program
increas
complianc
measur
benefici
effect
patient
includ
vulner
transplant
recipi
health
care
worker
respiratori
viral
ill
ideal
contact
transplant
recipi
contact
unavoid
possibl
measur
taken
prevent
transmiss
includ
mask
glove
limit
time
room
etc
transplant
center
develop
polici
penal
employe
absente
due
ill
educ
effort
emphas
mild
viral
symptom
health
care
worker
worker
might
tend
ignor
work
translat
acut
respiratori
failur
andor
longterm
loss
allograft
function
lung
recipi
educ
patient
famili
member
regard
avoid
outofhospit
exposur
well
import
earli
report
symptom
also
import
measur
role
antivir
therapi
noninfluenza
respiratori
virus
still
evolv
mani
center
use
ribavirin
prepar
treatment
symptomat
rsv
infect
sometim
parainfluenza
viru
metapneumoviru
infect
well
although
data
would
welcom
literatur
date
report
aerosol
ribavirin
inconveni
potenti
toxic
health
care
worker
led
studi
ribavirin
prepar
glanvil
et
al
describ
use
intraven
ribavirin
plu
oral
corticosteroid
lung
recipi
initi
fall
follow
recoveri
month
one
patient
develop
subsequ
bo
intraven
ribavirin
current
avail
unit
state
similarli
promis
preliminari
result
studi
pelaez
et
al
demonstr
preserv
allograft
function
group
lung
recipi
rsv
receiv
regimen
day
oral
ribavirin
combin
highdos
steroid
first
day
addit
fuehner
et
al
report
nonrandom
studi
patient
receiv
oral
ribavirin
compar
paramyxoviru
infect
wherea
group
declin
greater
percentag
ribavirintr
patient
recov
lung
function
within
month
vs
p
newonset
bo
within
month
occur
ribavirin
vs
nonribavirintr
patient
novel
therapi
also
develop
recent
studi
small
interf
rna
sirna
treatment
rsv
infect
demonstr
decreas
newonset
bo
progress
bo
day
treatment
group
n
compar
other
n
receiv
standard
care
rsv
infect
vs
p
like
avail
antivir
therapi
futur
would
make
larger
multicent
compar
effect
trial
includ
long
enough
follow
detect
effect
time
bo
desir
prevent
bacteri
infect
also
matter
infect
control
hand
hygien
immun
pneumococcu
pertussi
form
tdap
vaccin
adult
kept
date
ideal
updat
pretranspl
evalu
phase
given
result
gottlieb
et
al
regard
decreas
risk
patient
prior
pseudomona
colon
erad
strategi
enhanc
erad
like
produc
longterm
benefit
allograft
strategi
might
includ
individu
peritranspl
combin
system
inhal
antibiot
well
pretranspl
attent
potenti
reservoir
sinus
effect
vaccin
prevent
pseudomona
infect
colon
becom
avail
futur
would
import
intervent
effect
airway
intervent
stent
also
consid
foreign
bodi
airway
serv
nidu
bacteri
colon
albeit
import
intervent
prevent
postobstruct
pneumonia
allograft
dysfunct
demonstr
effect
azithromycin
protect
allograft
bo
bring
question
whether
prevent
infect
includ
subclin
infect
organ
lack
cell
wall
eg
chlamydophila
mycoplasma
simkania
might
one
mechan
contribut
protect
work
area
would
interest
risk
emerg
azithromycin
resist
organ
also
worthi
futur
studi
prevent
fungal
infect
inform
understand
risk
factor
exposur
relat
extern
environ
minim
includ
protect
effect
hospit
construct
transplant
recipi
educ
risk
marijuana
smoke
garden
farm
construct
work
compost
cave
explor
activ
consid
undertak
recov
initi
posttranspl
phase
begin
resum
normal
life
antifung
prophylaxi
util
mani
lung
transplant
program
frequent
use
azol
antifung
agent
inhal
amphotericin
prepar
combin
sometim
agent
regard
type
azol
use
shift
itraconazol
toward
voriconazol
time
howev
even
presenc
antifung
prophylaxi
breakthrough
fungal
infect
may
occur
fact
antifung
prophylaxi
may
select
certain
type
fungal
organ
eg
zygomycet
set
voriconazol
prophylaxi
protocol
bal
help
detect
fungal
colon
asymptomat
patient
might
prompt
either
chang
prophylaxi
increas
clinic
radiograph
monitor
occurr
fungal
infect
late
posttranspl
cours
discontinu
prophylaxi
might
relat
late
reject
environment
exposur
reservoir
nativ
lung
singlelung
transplant
recipi
enhanc
clinic
awar
patient
fall
group
help
prevent
pneumocysti
jiroveci
pneumonia
pjp
formerli
p
carinii
centerspecif
practic
vari
clinician
eg
gordon
et
al
recommend
continu
pjp
prophylaxi
longterm
lifelong
lung
recipi
uniqu
among
solid
organ
recipi
continu
signific
pjp
risk
beyond
first
year
trimethoprimsulfamethoxazol
commonli
use
agent
ad
benefit
prevent
sever
infect
toxoplasmosi
listeriosi
sulfaallerg
intoler
patient
monthli
aerosol
pentamidin
oral
dapson
oral
atovaquon
altern
prophylaxi
option
wherea
mani
previou
studi
focus
individu
infecti
agent
overal
microbi
ecolog
microbiom
allograft
may
fruit
area
studi
immun
respons
differ
infecti
agent
may
intertwin
ideal
futur
intervent
assess
term
alter
microbiom
rather
impact
one
particular
organ
grow
bodi
literatur
link
risk
newonset
progress
bo
varieti
infect
includ
cmv
herpesvirus
carv
bacteri
fungal
infect
although
result
differ
center
vari
appear
infect
play
role
bo
develop
least
set
mechanist
consider
eg
chemokin
anim
model
support
hypothesi
recent
studi
support
longer
durat
cmv
prophylaxi
role
colon
oppos
activ
infect
case
bacteria
fungi
role
subclin
viral
infect
allograft
area
consider
interest
extent
infect
trigger
bo
develop
newer
strategi
includ
vaccin
immunotherapi
enabl
earli
detect
intervent
import
provid
longterm
preserv
allograft
function
